SEC Form 4 · accession 0001140361-15-022892
Skye Bioscience, Inc. · SKYE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Gerald W. McLaughlin
Director
Period of report
May 29, 2015
Accepted (ET)
Jun 2, 2015 · 5:27 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001516551
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Series A Preferred StockF2,F1,F3 | $2.50 | May 29, 2015 | P | 10,000 | A | — | — | Common Stock | 10,000 | 10,000 | D |
| Common Stock Warrant (Right to Buy)F2 | $5.00 | May 29, 2015 | P | 2,000 | A | May 29, 2015 | May 29, 2020 | Common Stock | 2,000 | 2,000 | D |
Explanation of responses
- F1The Series A Convertible Preferred Stock are automatically convertible in accordance with the Issuer's Certificate of Designation and Certificate of Correction, which are included as exhibit 3.1 and 3.2, respectively, to the Issuer's Form 8-K filed on April 7, 2015, and do not have an expiration date.
- F2Pursuant to a Securities Purchase Agreement dated April 29, 2015, between the Reporting Person and the Issuer, the Reporting Person acquired 10,000 shares of Series A Preferred Stock and warrants to purchase an aggregate 2,000 shares of the Issuer's common stock at an exercise price of $5.00 per share in exchange for $25,000, or $2.50 per share.
- F3Subject to adjustment as specified in the Issuer's Certificate of Designation, which is included as exhibit 3.1 to the Issuer's Form 8-K filed on April 7, 2015.